IGFBP3 and cutaneous melanoma: Improved insulin sensitivity; reduction of IGF-1 and insulin signaling; increased IGFBP-3 and SHBG; inhibition of SREBP-1–mediated lipogenesis; weight loss benefits (notably in psoriasis and HS); alterations in lipid metabolism, including increased sphingomyelins (cutaneous melanoma)